Prostate-Specific Antigen Dynamics Predict Risk of Progression in Advanced Prostate Cancer Treated with Bicalutamide plus Castration
Prostate-Specific Antigen Dynamics Predict Risk of Progression in Advanced Prostate Cancer Treated with Bicalutamide plus Castration
复制标题
前列腺特异性抗原动态预测比卡鲁胺加去势治疗的晚期前列腺癌的进展风险
DOI：
--
复制
发表时间：
2002
影响因子：
1.6
通讯作者：
Andreas Schmidt
中科院分区：
文献类型：
--
作者：
J. Altwein;Andreas Schmidt
目的：探讨前列腺特异性抗原(PSA)动态变化在联合雄激素阻断(CAB)治疗中的预后价值。方法：317例局部晚期或转移性前列腺癌患者接受比卡鲁胺(50 mg，每日1次)联合醋酸格列林或手术去势治疗48周。考克斯的比例风险分析用于确定联合用药后PSA的下降是否预示着进展的延迟。结果：第4周和第12周的PSA水平是预测疾病进展的有统计学意义的预后标志。12周的PSA变化率也是一个有统计学意义的预后指标，尽管第4周的PSA变化率没有达到统计学意义。这些结果在统计上不如PSA水平的结果可靠。比卡鲁胺联合去势治疗晚期前列腺癌耐受性好且有效。结论：这些结果表明，4周和12周的PSA动态变化可以预测CAB治疗的晚期前列腺癌的进展时间。
Objective: The aim of this study was to investigate the prognostic value of prostate-specific antigen (PSA) dynamics in patients treated with combined androgen blockade (CAB). Methods: Patients with locally advanced or metastatic prostate cancer (n = 317) received bicalutamide (50 mg once daily) plus either goserelin acetate or surgical castration for 48 weeks. Cox’s proportional hazard analysis was used to determine whether the decline of PSA following the use of this combination is predictive of a delay in progression. Results: PSA levels at weeks 4 and 12 were statistically significant prognostic markers in predicting disease progression. The PSA rate of change to week 12 was also a statistically significant prognostic marker, although the PSA rate of change at week 4 did not reach statistical significance. These results were statistically less robust than those for PSA levels. Bicalutamide plus castration was well tolerated and effective in advanced prostate cancer. Conclusion: These results suggest that PSA dynamics at weeks 4 and 12 may predict time to progression in advanced prostate cancer treated with CAB.
使用人类前列腺特异性抗原监测前列腺癌。
影响因子：
11.2
作者：
Kuriyama,M;Wang,MC;Lee,CI;Papsidero,LD;Killian,CS;Inaji,H;Slack,NH;Nishiura,T;Murphy,GP;Chu,TM
通讯作者：
Chu,TM
影响因子：
158.5
作者：
Eisenberger, MA;Blumenstein, BA;Lowe, BA
通讯作者：
Lowe, BA
前列腺特异性抗原对于监测 B2 至 D1 期前列腺癌患者的预后重要性。
影响因子：
11.2
作者：
Killian,CS;Yang,N;Emrich,LJ;Vargas,FP;Kuriyama,M;Wang,MC;Slack,NH;Papsidero,LD;Murphy,GP;Chu,TM
通讯作者：
Chu,TM